Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Massimo Breccia; Roberto Latagliata; Fabio Stagno; Luigiana Luciano; Antonella Gozzini; Fausto Castagnetti; Carmen Fava; Francesco Cavazzini; Mario Annunziata; Antonella Russo Rossi; Patrizia Pregno; Elisabetta Abruzzese; Paolo Vigneri; Giovanna Rege-Cambrin; Simona Sica; Fabrizio Pane; Valeria Santini; Giorgina Specchia; Gianantonio Rosti; Giuliana Alimena

doi:10.3324/haematol.2011.041251

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

Massimo Breccia, Roberto Latagliata, Fabio Stagno, Luigiana Luciano, Antonella Gozzini, Fausto Castagnetti, Carmen Fava, Francesco Cavazzini, Mario Annunziata, Antonella Russo Rossi, Patrizia Pregno, Elisabetta Abruzzese, Paolo Vigneri, Giovanna Rege-Cambrin, Simona Sica, Fabrizio Pane, Valeria Santini, Giorgina Specchia, Gianantonio Rosti, Giuliana Alimena

Risultato della ricerca: Contributo in rivista › Articolo in rivista

47 Citazioni (Scopus)

Abstract

Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants of response to therapy in older patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer. The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived from relative risk estimates of a proportional hazard regression model using clinical data.

Lingua originale	English
pagine (da-a)	1457-1461
Numero di pagine	5
Rivista	Haematologica
Volume	96
DOI	https://doi.org/10.3324/haematol.2011.041251
Stato di pubblicazione	Pubblicato - 2011

Keywords

Aged
Antineoplastic Agents
Female
Humans
Incidence
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Medication Adherence
Pleural Effusion
Protein Kinase Inhibitors
Pyrimidines
Retrospective Studies
Thiazoles
Treatment Outcome

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3324/haematol.2011.041251

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint

Entra nei temi di ricerca di 'Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib'. Insieme formano una fingerprint unica.

Cita questo

Breccia, M., Latagliata, R., Stagno, F., Luciano, L., Gozzini, A., Castagnetti, F., Fava, C., Cavazzini, F., Annunziata, M., Rossi, A. R., Pregno, P., Abruzzese, E., Vigneri, P., Rege-Cambrin, G., Sica, S., Pane, F., Santini, V., Specchia, G., Rosti, G., & Alimena, G. (2011). Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica, 96, 1457-1461. https://doi.org/10.3324/haematol.2011.041251

@article{6388bd853bb5445aa38cd688ca050dbf,

title = "Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib",

abstract = "Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants of response to therapy in older patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer. The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived from relative risk estimates of a proportional hazard regression model using clinical data.",

keywords = "Aged, Antineoplastic Agents, Female, Humans, Incidence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Medication Adherence, Pleural Effusion, Protein Kinase Inhibitors, Pyrimidines, Retrospective Studies, Thiazoles, Treatment Outcome, Aged, Antineoplastic Agents, Female, Humans, Incidence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Medication Adherence, Pleural Effusion, Protein Kinase Inhibitors, Pyrimidines, Retrospective Studies, Thiazoles, Treatment Outcome",

author = "Massimo Breccia and Roberto Latagliata and Fabio Stagno and Luigiana Luciano and Antonella Gozzini and Fausto Castagnetti and Carmen Fava and Francesco Cavazzini and Mario Annunziata and Rossi, {Antonella Russo} and Patrizia Pregno and Elisabetta Abruzzese and Paolo Vigneri and Giovanna Rege-Cambrin and Simona Sica and Fabrizio Pane and Valeria Santini and Giorgina Specchia and Gianantonio Rosti and Giuliana Alimena",

year = "2011",

doi = "10.3324/haematol.2011.041251",

language = "English",

volume = "96",

pages = "1457--1461",

journal = "Haematologica",

issn = "1592-8721",

publisher = "Pavia : Fondazione Ferrata Storti",

}

Breccia, M, Latagliata, R, Stagno, F, Luciano, L, Gozzini, A, Castagnetti, F, Fava, C, Cavazzini, F, Annunziata, M, Rossi, AR, Pregno, P, Abruzzese, E, Vigneri, P, Rege-Cambrin, G, Sica, S, Pane, F, Santini, V, Specchia, G, Rosti, G & Alimena, G 2011, 'Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib', Haematologica, vol. 96, pagg. 1457-1461. https://doi.org/10.3324/haematol.2011.041251

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. / Breccia, Massimo; Latagliata, Roberto; Stagno, Fabio et al.
In: Haematologica, Vol. 96, 2011, pag. 1457-1461.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

AU - Breccia, Massimo

AU - Latagliata, Roberto

AU - Stagno, Fabio

AU - Luciano, Luigiana

AU - Gozzini, Antonella

AU - Castagnetti, Fausto

AU - Fava, Carmen

AU - Cavazzini, Francesco

AU - Annunziata, Mario

AU - Rossi, Antonella Russo

AU - Pregno, Patrizia

AU - Abruzzese, Elisabetta

AU - Vigneri, Paolo

AU - Rege-Cambrin, Giovanna

AU - Sica, Simona

AU - Pane, Fabrizio

AU - Santini, Valeria

AU - Specchia, Giorgina

AU - Rosti, Gianantonio

AU - Alimena, Giuliana

PY - 2011

Y1 - 2011

N2 - Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants of response to therapy in older patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer. The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived from relative risk estimates of a proportional hazard regression model using clinical data.

AB - Comorbidities may affect survival and choice of treatment among cancer patients. In fact, comorbidities have been identified as significant determinants of response to therapy in older patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer. The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived from relative risk estimates of a proportional hazard regression model using clinical data.

KW - Aged

KW - Antineoplastic Agents

KW - Female

KW - Humans

KW - Incidence

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Male

KW - Medication Adherence

KW - Pleural Effusion

KW - Protein Kinase Inhibitors

KW - Pyrimidines

KW - Retrospective Studies

KW - Thiazoles

KW - Treatment Outcome

KW - Aged

KW - Antineoplastic Agents

KW - Female

KW - Humans

KW - Incidence

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Male

KW - Medication Adherence

KW - Pleural Effusion

KW - Protein Kinase Inhibitors

KW - Pyrimidines

KW - Retrospective Studies

KW - Thiazoles

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/6037

U2 - 10.3324/haematol.2011.041251

DO - 10.3324/haematol.2011.041251

M3 - Article

SN - 1592-8721

VL - 96

SP - 1457

EP - 1461

JO - Haematologica

JF - Haematologica

ER -

Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96:1457-1461. doi: 10.3324/haematol.2011.041251